妊娠期糖尿病早期二甲双胍治疗:一项随机临床试验
这项在爱尔兰2个中心开展的双盲安慰剂对照试验纳入510人(535次妊娠)妊娠期糖尿病患者,比较早期二甲双胍与安慰剂对复合主要结局(启动胰岛素或孕32周或38周空腹血糖≥5.1 mmol/L)的影响。二甲双胍组该结局发生于150次妊娠(56.8%),安慰剂组167次妊娠(63.7%),组间差异为-6.9%(95%CI -15.1%至1.4%),相对风险为0.89(95%CI 0.78-1.02),P=0.13;作者得出结论:早期二甲双胍治疗在复合主要结局上并不优于安慰剂。
要点
- 二甲双胍组复合主要结局150/(56.8%),安慰剂组167/(63.7%),组间差异-6.9%(95%CI -15.1%至1.4%),未达统计学显著。
- 相对风险0.89(95%CI 0.78-1.02),P=0.13。
- 6项预设次要母体结局中3项利于二甲双胍组,包括启动胰岛素时间、自报毛细血管血糖控制和妊娠期体重增加。
核心结论
- 早期二甲双胍治疗在复合主要结局上并不优于安慰剂。
- 预设次要结局数据支持在更大规模临床试验中进一步研究二甲双胍。
研究设计与样本
- 双盲、安慰剂对照试验,在爱尔兰2个中心(一家三级医院和一家较小区域医院)开展。
- 参与者于2017年6月至2022年9月入组,随访至产后12周。
- 共510人(535次妊娠),按世界卫生组织2013年标准诊断为妊娠期糖尿病,按1:1随机分配至安慰剂或二甲双胍(最大剂量2500 mg)加常规照护。
主要发现
- 复合主要结局在二甲双胍组150次妊娠(56.8%)发生,在安慰剂组167次妊娠(63.7%)发生,组间差异为-6.9%(95%CI -15.1%至1.4%),相对风险0.89(95%CI 0.78-1.02),P=0.13,未达统计学显著。
- 6项预设次要母体结局中3项利于二甲双胍组,包括启动胰岛素时间、自报毛细血管血糖控制和妊娠期体重增加。
- 次要新生儿结局组间不同,二甲双胍组新生儿更小(平均出生体重更低、体重大于4 kg比例更低、大于90%百分位比例更低、 crown-heel length 更短),而新生儿重症监护需求、需呼吸支持的呼吸窘迫、需光疗的黄疸、严重先天畸形、新生儿低血糖或5分钟Apgar评分小于7的比例无差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文报告预设次要结局数据支持在更大规模临床试验中进一步研究二甲双胍。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Gestational diabetes is a common complication of pregnancy and the optimal management is uncertain. OBJECTIVE: To test whether early initiation of metformin reduces insulin initiation or improves fasting hyperglycemia at gestation weeks 32 or 38. DESIGN, SETTING, AND PARTICIPANTS: Double-blind, placebo-controlled trial conducted in 2 centers in Ireland (one tertiary hospital and one smaller regional hospital). Participants were enrolled from June 2017 through September 2022 and followed up until 12 weeks' postpartum. Participants comprised 510 individuals (535 pregnancies) diagnosed with gestational diabetes based on World Health Organization 2013 criteria. INTERVENTIONS: Randomized 1:1 to either placebo or metformin (maximum dose, 2500 mg) in addition to usual care. MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of insulin initiation or a fasting glucose level of 5.1 mmol/L or greater at gestation weeks 32 or 38. RESULTS: Among 510 participants (mean age, 34.3 years), 535 pregnancies were randomized. The primary composite outcome was not significantly different between groups and occurred in 150 pregnancies (56.8%) in the metformin group and 167 pregnancies (63.7%) in the placebo group (between-group difference, -6.9% [95% CI, -15.1% to 1.4%]; relative risk, 0.89 [95% CI, 0.78-1.02]; P = .13). Of 6 prespecified secondary maternal outcomes, 3 favored the metformin group, including time to insulin initiation, self-reported capillary glycemic control, and gestational weight gain. Secondary neonatal outcomes differed by group, with smaller neonates (lower mean birth weights, a lower proportion weighing >4 kg, a lower proportion in the >90% percentile, and smaller crown-heel length) in the metformin group without differences in neonatal intensive care needs, respiratory distress requiring respiratory support, jaundice requiring phototherapy, major congenital anomalies, neonatal hypoglycemia, or proportion with 5-minute Apgar scores less than 7. CONCLUSION AND RELEVANCE: Early treatment with metformin was not superior to placebo for the composite primary outcome. Prespecified secondary outcome data support further investigation of metformin in larger clinical trials. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02980276; EudraCT: 2016-001644-19.
引用
- Dunne F, Newman C, Alvarez-Iglesias A, et al. Early Metformin in Gestational Diabetes: A Randomized Clinical Trial. JAMA. 2023. PMID: 37786390. doi:10.1001/jama.2023.19869
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。